Published in Vaccine Weekly, November 21st, 2001
Given the extremely difficult economic circumstances since September of this year (2001), each company believes that shareholder value may be best protected by dividing CST development activities into separate cell therapeutic and drug and vaccine companies, which can each seek appropriate financing. Both companies plan to cooperate in areas of mutual interest and may enter into appropriate collaborative agreements in the future as opportunities arise.
Provisions of the restructuring include:
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly